Circulating soluble Fas concentration in breast cancer patients

Clinical Cancer Research

Volumn 5, Issue 11, 1999, Pages 3529-3533

  Ueno, Takayuki ^a   Toi, Masakazu ^a   Tominaga, Takeshi ^a  

^a TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; FAS LIGAND; TAMOXIFEN;

ADULT; AGED; APOPTOSIS; ARTICLE; BREAST CANCER; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECEPTOR BINDING; TISSUE DISTRIBUTION;

ADULT; AGE FACTORS; ANTIGENS, CD95; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LIVER NEOPLASMS; LYMPHATIC METASTASIS; MALE; MENOPAUSE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROGNOSIS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RECURRENCE; REFERENCE VALUES; SEX CHARACTERISTICS; SURVIVAL RATE; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 0032737486     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Itoh, N., Yonehara, S., Ishii, A., Yonehara, M., Mizushima, S., Sameshima, M., Hase, A., Seto, Y., and Nagata, S. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell, 66: 233-243, 1991.
2. Leithauser, F., Dhein, J., Mechtersheimer, G., Koretz, K., Bruderlein, S., Henne, C., Schmidt, A., Debatin, K. M., Krammer, P. H., and Moller, P. Constitutive and induced expression of apo-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and malignant cells. Lab. Investig., 69: 415-429, 1993.
3. Nagata, S., and Golstein, P. The Fas death factor. Science (Washington DC), 267: 1449-1456, 1995.
4. Peng, S. L., Robert, M. E., Hayday, A. C., and Craft, J. A tumor-suppressor function for Fas (CD95) revealed in T cell-deficient mice. J. Exp. Med., 184: 1149-1154, 1996.
5. Zörnig, M., Grzeschiczek, A., Kowalski, M-B., Hartmann, K-U., and Möröy, T. Loss of Fas/Apo-1 receptor accelerates lymphomagenesis in Em L-MYC transgenic mice but not in animals infected with MoMuLV. Oncogene, 10: 2397-2401, 1995.
6. Friesen, C., Herr, I., Krammer, P. H., and Debatin, K-M. Involvement of CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat. Med., 2: 574-577, 1996.
7. Micheau, O., Solary, E., Hammann, A., Martin, F., and Dimanche-Boitrel, M-T. Sensitization of cancer cells treated with cytotoxic drugs to Fas-mediated cytotoxicity. J. Natl. Cancer Inst., 89: 783-789, 1997.
8. Cheng, J., Zhou, T., Liu, C., Shapiro, J. P., Brauer, M. J., Kiefer, M. C., Barr, P. J., and Mountz, J. D. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science (Washington DC), 263: 1759-1762, 1994.
9. Cascino, I., Fiucci, G., Papoff, G., and Ruberti, G. Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. J. Immunol., 154: 2706-2713, 1995.
10. Papoff, G., Cascino, I., Eramo, A., Starace, G., Lynch, D. H., and Ruberti, G. An N-terminal domain shared by Fas/Apo-1 (CD95) soluble variants prevents cell death in vitro. J. Immunol., 156: 4622-4630, 1996.
11. Knipping, E., Debatin, K-M., Stricker, K., Heilig, B., Eder, A., and Krammer, P. H. Identification of soluble APO-1 in supernatants of human B-and T-cell lines and increased serum levels in B-and T-cell leukemias. Blood, 85: 1562-1569, 1995.
12. Midis, G. P., Shen, Y., and Owen-Schaub, L. B. Elevated soluble Fas (sFas) levels in nonhematopoietic human malignancy. Cancer Res., 56: 3870-3874, 1996.
13. Yufu, Y., Choi, I., Hirase, N., Tokoro, A., Noguchi, Y., Goto, T., Uike, N., and Kozuru, M. Soluble Fas in the serum of patients with non-Hodgkin's lymphoma: higher concentration in angioimmunoblastic T-cell lymphoma. Am. J. Hematol., 58: 334-336, 1998.
14. Jodo, S., Kobayashi, S., Nakajima, Y., Matsunaga, T., Nakayama, N., Ogura, N., Kayagaki, N., Okumura, K., and Koike, T. Elevated serum levels of soluble Fas/APO-1 (CD95) in patients with hepatocellular carcinoma. Clin. Exp. Immunol., 112: 166-171, 1998.
15. Mizutani, Y., Yoshida, O., and Bonavida, B. Prognostic significance of soluble Fas in the serum of patients with bladder cancer. J. Urol., 160: 571-576, 1998.
16. Owen-Schaub, L. B., Angelo, L. S., Radinsky, R., Ware, C. F., Gesner, T. G., and Bartos, D. P. Soluble Fas/APO-1 in tumor cells: a potential regulator of apoptosis? Cancer Lett., 94: 1-8, 1995.
17. Natoli, G., Ianni, A., Costanzo, A., Petrillo, G. D., Ilari, I., Chirillo, P., Balsano, C., and Levrero, M. Resistance to Fas-mediated apoptosis in human hepatoma cells. Oncogene, 11: 1157-1164, 1995.
18. Iio, S., Hayashi, N., Mita, E., Ueda, K., Mochizuki, K., Hiramatsu, N., Kanto, T., Sasaki, Y., Kasahara, A., and Hori, M. Serum levels of soluble Fas antigen in chronic hepatitis C patients. J. Hepatol., 29: 517-523, 1998.
19. Walker, P. R., Saas, P., and Dietrich, P-Y. Role of Fas ligand (CD95L) in immune escape. The tumor cell strikes back. J. Immunol., 158: 4521-4524, 1997.
20. Nagata, S. Apoptosis by death factor. Cell, 88: 355-365, 1997.
21. Hahne, M., Rimoldi, D., Schroter, M., Romero, P., Schreier, M., French, L. E., Schneider, P., Bornand, T., Fontana, A., Lienard, D., Cerottini, J-C., and Tschopp, J. Melanoma cell expression of Fas (Apo-1/CD95) ligand: implications for tumor immune escape. Science (Washington DC), 274; 1363-1366, 1996.
22. Strand, S., Hofmann, W. J., Hug, H., Muller, M., Otto, G., Strand, D., Mariani, S. M., Stremmel, W., Krammer, P. H., and Galle, P. R. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand expressing tumor cells: a mechanism of immune evasion. Nat. Med., 2: 1361-1366, 1996.
23. O'Connell, J., O'Sullivan, G. C., Collins, J. K., and Shanahan, F. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J. Exp. Med., 184: 1075-1082, 1996.
24. Tanaka, M., Suda, T., Haze, K., Nakamura, N., Sato, K., Kimura, F., Motoyoshi, K., Mizuki, M., Tagawa, S., Ohga, S., Hatake, K., Drummond, A. H., and Nagata, S. Fas ligand in human serum. Nat. Med., 2: 317-322, 1996.
25. Seishima, M., Takemura, M., Saito, K., Sano, H., Minatoguchi, S., Fujiwara, H., Hachiya, T., and Noma, A. Highly sensitive ELISA for soluble Fas in serum: increased soluble Fas in the elderly. Clin. Chern., 42: 1911-1914, 1996.
26. Lee, S. H, Kim, S. Y., Lee, J. Y., Shin, M. S., Dong, S. M., Na, E. Y., Park, W. S., Kim, K. M., Kim, C. S., Kim, S. H., and Yoo, N. J. Detection of soluble Fas mRNA using in situ reverse transcription-polymerase chain reaction. Lab. Investig., 78: 453-459, 1998.
27. Krams, S. M., Fox, C. K., Beatty, P. R., Cao, S., Villanueva, J. C., Esquivel, C. O., and Martinez, O. M. Human hepatocytes produce an isoform of Fas that inhibits apoptosis. Transplantation. 65: 713-721, 1998.
28. Weller, M., Malipielo, U., Rensing-Ehl, A., Barr, P. J., and Fontana, A. Fas/APO-1 gene transfer for human malignant glioma. Cancer Res., 55: 2936-2944, 1995.
29. Cai, Z., Stancou, R., Körner, M., and Chouaib, S. Impairment of Fas-antigen expression in Adriamycin-resistant but not TNF-resistant MCF7 tumor cells. Int. J. Cancer, 68: 535-546, 1996.